Skip to main content
SpringerLink
Log in

ICER report update says evolocumab lacks mortality benefit

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. HMG-CoA reductase inhibitors

Reference

  • Institute for Clinical and Economic Review. Institute for Clinical and Economic Review's "New Evidence Update" on PCKS9 Inhibitors Highlights Lack of Mortality Benefit With Evolocumab. Internet Document : 13 Jun 2017. Available from: URL: https://icer-review.org/announcements/pcsk-neu-clinical/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICER report update says evolocumab lacks mortality benefit. PharmacoEcon Outcomes News 780, 1 (2017). https://doi.org/10.1007/s40274-017-4053-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4053-1

Search

Navigation